查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009203

疫苗契约製造市场规模、份额、趋势和预测：按疫苗类型、工作流程、应用和地区划分，2026-2034 年

Vaccine Contract Manufacturing Market Size, Share, Trends and Forecast by Vaccine Type, Workflow, Application, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2025年全球疫苗契约製造（ CMO）市场规模为33亿美元。预计到2034年，该市场规模将达到65亿美元，2026年至2034年的复合年增长率（CAGR）为8.03%。北美目前在主导，2025年市占率达36%。世界各国政府将免疫接种作为公共卫生策略的基石，并透过津贴、补贴和采购合约来确保疫苗的及时供应。此外， 契约製造的扩张也推动了疫苗契约製造市场份额的成长。

受感染疾病蔓延、人们对医疗保健日益重视以及为应对未来大流行病做好准备等因素推动，全球对疫苗的需求不断增长，市场正在蓬勃发展。高昂的研发和生产成本阻碍了製药和生物技术公司投资建设大规模设施，导致越来越多的企业将生产外包给拥有成熟专业知识和合规能力的契约製造生产商 (CMO)。拓展先进疫苗的开发平臺，包括信使核糖核酸 (mRNA) 和病毒载体平台，需要 CMO 更擅长的专业技术。此外，对灵活可扩展生产能力的需求，以及缩短产品上市时间的压力，使得外包成为策略选择。

由于多种因素，美国正崛起为契约製造市场的领先地区。公众对健康、免疫计划以及应对新兴感染疾病的日益关注，推动了契约製造市场的成长。高昂的研发和生产成本，加上严格的监管要求，促使製药和生物技术公司与经验丰富的契约製造合作，这些製造商能够提供合规方面的专业知识、先进的设施和成本效益。随着美国生物製药产品线的扩展，包括mRNA疫苗和病毒载体疫苗，对专业技术和灵活的生产能力的需求日益增长，许多公司倾向于将这些业务外包。根据IMARC集团预测，到2033年，美国生物製药市场规模预计将达到3,710亿美元，2025年至2033年的复合年增长率（CAGR）为7.4%。

疫苗契约製造市场的发展趋势：

人们对疫苗接种的认识不断提高

人们对疫苗接种的日益关注为契约製造市场创造了有利前景。随着个人、社区和政府认识到疫苗在预防感染疾病和减轻医疗负担方面发挥的关键作用，全球免疫接种计划正在不断扩展。疫苗接种透过减少抗生素的使用和预防疾病，在改善人类和动物健康方面发挥着至关重要的作用。根据世界卫生组织（WHO）预测，截至2024年8月，疫苗接种每年将预防350万至500万人死于白喉、破伤风、百日咳、流感和麻疹等疾病。这种日益增强的意识不仅提高了疫苗接种率，也促使製药和生物技术公司迅速扩大生产规模，而这通常是透过外包给契约製造製造商来实现的。契约製造（CMO）提供所需的专业知识、基础设施和生产能力，以高效满足不断增长的需求，同时确保品质和合规标准。

扩大政府支持

政府支持力度的加强是契约製造市场的关键趋势之一。世界各国政府都将免疫接种作为公共卫生策略的基石，并透过提供津贴、补贴和采购合约来确保疫苗的及时供应。这种支援降低了製药和生物技术公司的财务风险，使它们能够将生产外包给拥有先进基础设施和监管专业知识的专业合约生产机构（CMO）。此外，官民合作关係正在促进创新，提高供应链韧性，并扩大全球疫苗的可及性。在紧急情况下，各国政府也正在简化监管流程，并加速核准和生产进度。这种积极的支持不仅增强了人们对契约製造的信心，也确保了合约生产机构在高效满足国内外疫苗接种需求方面发挥关键作用。根据联合国儿童基金会在 2025 年 3 月进行的一项宣传活动效果调查，在卫生署和联合国儿童基金会开展轮状病毒疫苗媒体宣传活动后，94% 的家长和看护者表示对接种疫苗的兴趣有所增加，78% 的家长和监护人表示对疫苗的成分有「清晰」或「非常清晰」的了解。

SARS-CoV-2 活性增强

SARS-CoV-2病毒活动加剧，加速了对疫苗、加强针以及旨在应对新出现的变异株的新一代疫苗的需求。根据世界卫生组织的数据，全球SARS-CoV-2病毒活动自2025年2月中旬起持续上升，检测阳性率达到11%，为2024年7月以来的最高水准。病毒的持续传播凸显了大规模、灵活生产能力的重要性，而製药公司通常透过外包给合约生产商（CMO）来实现这一目标。契约製造生产商具备专业知识和扩充性，能够快速调整生产流程以适应更新的疫苗，从而确保全球及时供应。病毒变异株的演变以及反覆出现的感染浪潮的不可预测性，使得维持强大的疫苗研发管线变得尤为重要，也进一步增加了对合约生产商的依赖。此外，SARS-CoV-2病毒的出现提高了人们对疫苗研发准备的关注度，并刺激了对mRNA平台等先进技术的投资，而合约生产商在这些技术中发挥着至关重要的作用。根据对契约製造市场的预测，病毒的持续传播将继续推动市场扩张。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球疫苗契约製造市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依疫苗类型划分

  • 衰减
  • 失活
  • 次单元类型
  • 类毒素类型
  • 基于DNA的

第七章 市场区隔：依工作流程

  • 下游工艺
    • 主要部分
      • 填充和表面处理工程
      • 分析和品管(QC) 测试
      • 包装
  • 上游工程
    • 主要部分
      • 哺乳动物表达系统
      • 细菌表现系统
      • 酵母表现系统
      • 桿状病毒/昆虫表现系统
      • 其他的

第八章 市场区隔：依应用领域划分

  • 对人类而言
  • 兽用

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited（Charles River Laboratories International Inc.）
    • Cytovance Biologics Inc.（Hepalink USA Inc.）
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
Product Code: SR112026A3872

The global vaccine contract manufacturing market size was valued at USD 3.3 Billion in 2025. The market is projected to reach USD 6.5 Billion by 2034, exhibiting a CAGR of 8.03% from 2026-2034. North America currently dominates the market, holding a market share of 36% in 2025. Governments worldwide are prioritizing immunization as a key public health strategy, offering grants, subsidies, and procurement commitments to ensure timely access to vaccines. Besides this, the expansion of contract manufacturing organizations (CMOs) is propelling the vaccine contract manufacturing market share.

The market is being propelled by rising global demand for vaccines, driven by increasing infectious disease prevalence, greater focus on preventive healthcare, and preparedness for future pandemics. High research and production costs often discourage pharmaceutical and biotech firms from investing in large-scale facilities, leading them to outsource to contract manufacturers with established expertise and regulatory compliance capabilities. The expanding pipeline of advanced vaccines, including messenger ribonucleic acid (mRNA) and viral vector platforms, requires specialized technologies that CMOs are better positioned to provide. Additionally, the need for flexible and scalable production capacity, combined with the pressure to reduce time-to-market, is making outsourcing a strategic choice.

The United States has emerged as a major region in the vaccine contract manufacturing market owing to many factors. Rising focus on public health, immunization programs, and preparedness against emerging infectious diseases is propelling the vaccine contract manufacturing market growth. High research and development (R&D) and production costs, along with stringent regulatory requirements, are encouraging pharmaceutical and biotech firms to collaborate with experienced contract manufacturers that offer compliance expertise, advanced facilities, and cost efficiency. The country's growing pipeline of biologics, including mRNA and viral vector vaccines, requires specialized technologies and flexible manufacturing capacities that many firms prefer to outsource. As per the IMARC Group, the United States biologics market is set to attain USD 371.0 Billion by 2033, exhibiting a CAGR of 7.4% from 2025-2033.

VACCINE CONTRACT MANUFACTURING MARKET TRENDS:

Increasing awareness about vaccination

The growing awareness about vaccination is offering a favorable vaccine contract manufacturing market outlook. As individuals, communities, and governments are recognizing the critical role of vaccines in preventing infectious diseases and reducing healthcare burdens, immunization programs are being expanded globally. Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents ailments. According to the WHO, as of August 2024, vaccination averted 3.5 Million to 5 Million fatalities annually from illnesses, such as diphtheria, tetanus, pertussis (whooping cough), influenza, and measles. This heightened consciousness is not only boosting vaccination rates but also encouraging pharmaceutical and biotech companies to scale up production quickly, often through outsourcing to contract manufacturers. CMOs provide the expertise, infrastructure, and capacity needed to meet this increasing demand efficiently while maintaining quality and compliance standards.

Rising government support

Rising government support is among the major vaccine contract manufacturing market trends. Governments worldwide are prioritizing immunization as a key public health strategy, offering grants, subsidies, and procurement commitments to ensure timely access to vaccines. This backing reduces financial risks for pharmaceutical and biotech companies, enabling them to outsource manufacturing to specialized CMOs with advanced infrastructure and regulatory expertise. Additionally, public-private partnerships are fostering innovations, improving supply chain resilience, and expanding global vaccine access. Governments are also streamlining regulatory pathways during emergencies, accelerating approval and production timelines. Such proactive support is not only strengthening confidence in contract manufacturing but also ensuring CMOs play a vital role in meeting both domestic and international vaccination needs efficiently. A UNICEF campaign effectiveness survey conducted in March 2025 found that 94% of parents and caregivers expressed increased interest in vaccination, after the Rota Vaccine media campaign by the Ministry of Health and UNICEF, and 78% reported they understood the vaccine 'clearly' or 'very clearly.'

Increasing SARS-CoV-2 activity

Rising SARS-CoV-2 activity is catalyzing the demand for vaccines, booster shots, and next-generation formulations designed to address emerging variants. According to WHO data, worldwide SARS-CoV-2 activity has been increasing since mid-February 2025, with the test positivity rate attaining 11%, the highest recorded since July 2024. Continued viral circulation highlights the need for large-scale, flexible production capacity that pharmaceutical firms often achieve through outsourcing to CMOs. Contract manufacturers provide the expertise and scalability to rapidly adapt production processes for updated vaccines, ensuring timely global supply. The unpredictability of variant evolution and recurring infection waves is reinforcing the importance of maintaining strong vaccine pipelines, which is further increasing reliance on CMOs. Additionally, SARS-CoV-2 has accelerated awareness about vaccine preparedness and encouraged investments in advanced technologies like mRNA platforms, where CMOs play a pivotal role. As per the vaccine contract manufacturing market forecast, the ongoing viral activity will continue to fuel the market expansion.

VACCINE CONTRACT MANUFACTURING INDUSTRY SEGMENTATION:

Analysis by Vaccine Type:

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Inactivated holds 33.4% of the market share in 2025. These vaccines use killed or non-replicating pathogens, making them safer for individuals with weakened immune systems and suitable for mass immunization programs. Their production process is standardized and well-understood, allowing contract manufacturers to scale up with fewer risks compared to newer or more complex vaccine platforms. Additionally, regulatory bodies worldwide have long experience approving inactivated vaccines, which speeds up licensing and market access. These vaccines are extensively used against influenza, polio, hepatitis A, rabies, and several other infectious diseases, ensuring steady demand from both public and private healthcare providers. CMOs benefit from consistent demand, established production technologies, and the ability to serve large-scale vaccination campaigns, especially in developing regions. Furthermore, inactivated vaccines are often more stable and easier to store and transport compared to some modern alternatives, which supports global distribution.

Analysis by Workflow:

  • Downstream
    • Fill and Finish Operations
    • Analytical and QC Studies
    • Packaging
  • Upstream
    • Mammalian Expression Systems
    • Bacterial Expression Systems
    • Yeast Expression Systems
    • Baculovirus/Insect Expression Systems
    • Others

Downstream (fill and finish operations, analytical and QC studies, and packaging) accounts for 58% of the market share. Downstream processes are critical in ensuring the purity, safety, and effectiveness of vaccines before distribution. While upstream activities focus on cultivation and production, downstream operations, such as purification, filtration, separation, and formulation, ensure that vaccines meet stringent regulatory and quality standards. These processes are often more complex, resource-intensive, and cost-demanding, making them a major contributor to overall manufacturing expenditure. Contract manufacturers with advanced downstream capabilities add value by improving yield, maintaining consistency across large batches, and reducing contamination risks. With rising demand for sophisticated vaccines like mRNA and viral vector platforms, the downstream stage has gained greater importance in handling delicate biomolecules. Its pivotal role in product validation, compliance, and large-scale readiness is driving its dominance in the market, as no vaccine can be commercialized without rigorous downstream processing.

Analysis by Application:

  • Human Use
  • Veterinary

Human use holds 85% of the market share. Human use vaccines are prioritized globally because of their vital function in averting infectious diseases, lowering morbidity and mortality, and supporting public health initiatives. Governments, international health organizations, and private healthcare providers are investing in large-scale immunization programs, creating a continuous need for reliable vaccine supply. Pharmaceutical and biotech companies often rely on contract manufacturers to meet this demand efficiently, leveraging their expertise, advanced facilities, and compliance with stringent regulatory standards. The rising prevalence of infectious diseases, coupled with pandemic preparedness and emerging vaccine technologies, such as mRNA, viral vector, and recombinant platforms, is further intensifying production requirements. While veterinary vaccines are essential, the scale, urgency, and societal impact of human vaccination far exceed other applications, making human use the dominant driver of growth in the market worldwide.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for a share of 36%, enjoys the leading position in the market. The region is noted for its strong biotechnology and pharmaceutical ecosystem, advanced infrastructure, and high investments in R&D activities. The region is home to leading CMOs and technology providers that offer cutting-edge capabilities in biologics, mRNA, and viral vector vaccine production, making it a hub for innovations and large-scale manufacturing. Stringent regulatory frameworks ensure high standards of quality and compliance, which enhances trust in vaccines manufactured in the region. Additionally, the presence of a well-established healthcare system, government funding for immunization programs, and strong academic-industry collaborations are accelerating vaccine development and outsourcing activities. In March 2025, Canada revealed a commitment of CAD 675 Million in fresh funding for Gavi, the Vaccine Alliance's upcoming strategic phase from 2026 to 2030, known as 'Gavi 6.0.' The commitment will aid Gavi's goal to safeguard a greater number of individuals from more diseases at an accelerated pace.

KEY REGIONAL TAKEAWAYS:

UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The United States holds 88% of the market share in North America. The United States vaccine contract manufacturing market is primarily driven by the increasing prevalence of infectious diseases and the resurgence of certain vaccine-preventable illnesses. In line with this, the growing public and private investments in strengthening domestic manufacturing infrastructure and capacity are fueling the market expansion. As such, in April 2025, Merck initiated the development of a USD 1 Billion, 470,000-square-foot biologics facility in Wilmington, Delaware to manufacture KEYTRUDA and future therapies, resulting in over 500 permanent jobs and enhancing US manufacturing and innovation capabilities. Similarly, the broadening of novel vaccine platforms, including mRNA, recombinant, and vector-based technologies, is bolstering the market growth. The heightened need to meet stringent regulatory standards is also encouraging pharmaceutical companies to collaborate with experienced CMOs for compliance and quality assurance. Additionally, continual advancements in single-use bioprocessing technologies, improving production flexibility and reducing timelines, are propelling the market growth. The heightened focus on pandemic preparedness and vaccine stockpiling is driving long-term outsourcing contracts. Furthermore, the rise of personalized and therapeutic vaccines is diversifying service requirements, while the United States' skilled biologics workforce continues to attract global manufacturing partnerships.

EUROPE VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The European market is experiencing growth due to rising demand for pandemic preparedness measures, encouraging governments to establish large-scale production partnerships. In accordance with this, the increasing focus on regional self-sufficiency in vaccine supply is driving localized production agreements. The rising presence of strong biopharmaceutical hubs in Germany, Belgium, and the Netherlands, which are attracting significant investments in advanced facilities, is fostering the market expansion. Accordingly, in June 2025, Leyden Labs obtained EUR 20 Million from the European Investment Bank through HERA Invest to promote its pan-influenza nasal spray and pandemic readiness initiatives, aiding EU biodefense, antibiotic resistance, and respiratory virus safety projects. Moreover, ongoing advancements in bioprocessing technologies are improving scalability, efficiency, and quality standards. The heightened regulatory requirements are also motivating pharmaceutical companies to partner with experienced CMOs to ensure compliance. Furthermore, the rising prevalence of infectious diseases and the sustained demand for large-volume manufacturing are supporting the market growth. Besides this, the expansion of Europe's vaccine pipeline is diversifying service needs, creating lucrative opportunities in the market.

ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The Asia-Pacific market for vaccine contract manufacturing is largely influenced by the rapid broadening of national immunization programs. Similarly, the growing pipeline of next-generation vaccines, including mRNA, recombinant, and vector-based platforms, is fostering opportunities for specialized CMOs. The strategic collaborations between multinational pharmaceutical companies and regional manufacturers are accelerating technology transfer and ensuring compliance with global quality standards. Similarly, heightened focus on pandemic preparedness, prompting long-term manufacturing partnerships to secure supply resilience, is propelling the market growth. The region's cost advantages in skilled labor, raw materials, and operational efficiency are also attracting global outsourcing projects. Moreover, Asia Pacific's rising role as a competitive hub for vaccine production and export is reinforcing its prominence in the market. As such, in January 2025, Bharat Biotech allocated INR 1,500 Crore to establish a vaccine hub in Odisha that would produce eight Billion doses each year, generate 3,500 jobs, and manufacture vaccines for cholera, malaria, and polio, with plans for Chikungunya and Zika vaccines in the future.

LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

In Latin America, the market is advancing due to the expansion of government-led immunization programs aimed at achieving greater regional vaccine self-sufficiency. The Ministry of Health in Brazil announced that starting in 2026, 60 Million dengue vaccine doses will be manufactured annually. The initial phase will focus on people between the ages of 2 and 59, with an investment of BRL 68 Million allocated for the first production. Furthermore, rising investments in biopharmaceutical infrastructure, particularly in Brazil and Mexico, are strengthening large-scale production capacity. Additionally, strategic technology transfer agreements with multinational pharmaceutical companies are enabling the utilization of advanced manufacturing platforms and adherence to global quality standards.

MIDDLE EAST AND AFRICA VACCINE CONTRACT MANUFACTURING MARKET ANALYSIS

The Middle East and Africa market is accumulating traction due to government-led initiatives aimed at promoting regional vaccine production capacity and decreasing dependence on imports. In addition to this, numerous collaborations with global pharmaceutical companies, enabling access to advanced manufacturing technologies and regulatory expertise, are impelling the market growth. Similarly, the increasing prevalence of infectious diseases is driving the demand for locally produced vaccines to ensure a timely supply for national immunization programs. Apart from this, expanded public health funding is strengthening long-term vaccine manufacturing sustainability across the region. Accordingly, in June 2025, the Department of Health in Abu Dhabi sealed agreements with Sanofi, Boehringer Ingelheim, and Abbott to enhance vaccine production, promote R&D activities, localize drug manufacturing, and reinforce the Emirate's international life sciences standing.

COMPETITIVE LANDSCAPE:

Key players are providing the technical expertise, infrastructure, and scalability needed to meet the growing global demand. These companies are investing heavily in advanced bioprocessing technologies, quality control systems, and regulatory compliance, enabling pharmaceutical and biotech firms to outsource vaccine production with confidence. By offering specialized capabilities, such as mRNA, viral vector, and recombinant vaccine manufacturing, key players are helping to accelerate development timelines and ensure consistent product quality. Their global presence also allows flexible capacity and localized production, improving supply chain resilience and accessibility. Moreover, strategic collaborations, joint ventures, and partnerships with innovators are strengthening the market by expanding service portfolios. In this way, key players act as enablers, ensuring efficiency, affordability, and speed in vaccine manufacturing. For instance, in October 2024, LenioBio collaborated with ReciBioPharm to broaden its CEPI-supported ALiCE cell-free protein expression technology for quicker vaccine manufacturing. The partnership involved transferring technology to Portugal for manufacturing at a 10-liter scale, aiding the 100 Days Mission to expedite the development of vaccines and preparedness for new health challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the vaccine contract manufacturing market?

2. What is the future outlook of vaccine contract manufacturing market?

3. What are the key factors driving the vaccine contract manufacturing market?

4. Which region accounts for the largest vaccine contract manufacturing market share?

5. Which are the leading companies in the global vaccine contract manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2025
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2025
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2025
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million USD), 2026-2034
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players